Oral etoposide for treatment and/or maintenance treatment of recurrent epithelial ovarian cancer.
Why it is important to do this review:
Oral etoposide is a potential candidate for treatment and/or maintenance therapy of recurrent EOC, as it does not exhibit cross-resistance to platinum or paclitaxel which are used as the first-line chemotherapeutic agents (Nagano 2016). The specific situations where etoposide has been used have been very diverse, as have the modalities of its administration, and therefore the possible alternatives are also numerous. For this reason, there are still some uncertainties about the effectiveness and safety of oral etoposide compared with other salvage or maintenance chemotherapeutic agents for recurrent disease. Therefore, a Cochrane Review based on evidence from randomized controlled trials is needed to assess the clinical therapeutic efficacy and adverse effects of oral etoposide either as a single agent or combined therapy in the second-line treatment and/or maintenance treatment of women with recurrent EOC.
To assess the clinical therapeutic efficacy and adverse effects of oral etoposide as treatment and/or maintenance treatment in women with recurrent epithelial ovarian cancer.